The Ministry of Health, Labor and Welfare (MHLW) sent an alert to doctors’ groups and prefectural authorities on January 28 about the risk of fulminant type 1 diabetes carried by Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab). The company revised its…
To read the full story
Related Article
- Add Type 1 Diabetes to Opdivo Label: MHLW
November 26, 2015
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





